Skip to content

On-Eye Evaluation of Contact Lens Rotation Marks

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02055404
Enrollment
3
Registered
2014-02-05
Start date
2013-02-28
Completion date
2013-02-28
Last updated
2014-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Error

Keywords

astigmatism, toric, contact lenses, daily disposable contact lenses, molded mark, rotation mark

Brief summary

The purpose of this study was to select the size of the molded rotation mark for a new toric contact lens by comparing the visibility of various molded rotation marks.

Detailed description

Participants wore the test and control products contralaterally (in each eye separately) for 2 hours, during which the Investigator assessed the various molded rotation marks for visibility. Each participant was assessed by 10 investigators.

Interventions

DEVICEDelefilcon A spherical contact lens with molded marks

Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.

Hydrogel toric contact lens for daily wear, daily disposable use

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Sign Informed Consent document. * Best corrected distance visual acuity (VA) greater than or equal to 20/25 in each eye. * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* History of any ocular surgery or ocular injury within 12 weeks of study enrollment. * Any ocular disease, infection, inflammation, or abnormality that contraindicates contact lens (CL) wear. * History of herpetic keratitis. * Slit-lamp findings greater than grade 2 at baseline. * Any use of systemic or ocular medications for which CL wear could be contraindicated. * Inactive corneal neovascularization greater than 1 millimeter of penetration. * A clinically significant dry eye not responding to treatment. * History of refractive surgery. * Participation in a clinical study within the previous 30 days. * Other protocol-defined

Design outcomes

Primary

MeasureTime frameDescription
Visibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)Day 1Each lens (containing 8 rotation marks and one reference mark, in total 9 marks) was assessed for visibility by 10 investigators using the following scale: N/A; Not visible; Slightly visible, not acceptable; Slightly visible, acceptable; Clearly visible; More visible than necessary. Visibility assessments were made after all marks had been evaluated. S9 Mark (test lens) functioned as a starting marker only and was not rated. The control lens was not used as a comparison, but rather as a reference for what a mark looks like on a commercial product. Visibility of Rotation Mark is reported as the percentage of assessments rating the rotation mark as Clearly visible or Slightly visible, acceptable.

Participant flow

Recruitment details

Participants were recruited from 1 US study center.

Pre-assignment details

This reporting group includes all enrolled participants.

Participants by arm

ArmCount
Overall Study
Delefilcon A spherical contact lens with molded marks and etafilcon A toric contact lens worn contralaterally (1 in each eye) for approximately 2 hours
3
Total3

Baseline characteristics

CharacteristicOverall Study
Age, Continuous46.0 years
STANDARD_DEVIATION 21.3
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
1 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 30 / 3
serious
Total, serious adverse events
0 / 30 / 3

Outcome results

Primary

Visibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)

Each lens (containing 8 rotation marks and one reference mark, in total 9 marks) was assessed for visibility by 10 investigators using the following scale: N/A; Not visible; Slightly visible, not acceptable; Slightly visible, acceptable; Clearly visible; More visible than necessary. Visibility assessments were made after all marks had been evaluated. S9 Mark (test lens) functioned as a starting marker only and was not rated. The control lens was not used as a comparison, but rather as a reference for what a mark looks like on a commercial product. Visibility of Rotation Mark is reported as the percentage of assessments rating the rotation mark as Clearly visible or Slightly visible, acceptable.

Time frame: Day 1

Population: The analysis population includes all enrolled participants. Assessments from all 10 investigators were analyzed, hence sample size for each rotational mark is 30.

ArmMeasureValue (NUMBER)
S1 MarkVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)42.9 Percentage of assessments
S2 MarkVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)71.4 Percentage of assessments
S3 MarkVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)78.6 Percentage of assessments
S4 MarkVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)46.4 Percentage of assessments
S5 MarkVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)71.4 Percentage of assessments
S6 MarkVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)82.1 Percentage of assessments
S7 MarkVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)78.6 Percentage of assessments
S8 MarkVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)75.0 Percentage of assessments
ControlVisibility of Rotation Mark (Clearly Visible, Slightly Visible Acceptable)93.3 Percentage of assessments

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026